Elaprase launched for Hunter syndrome

Shire has launched Elaprase (idursulfase), indicated for the long-term treatment of patients with Hunter syndrome (also known as mucopolysaccharidosis II).

Elaprase is administered at a dose of 0.5mg/kg weekly by intravenous infusion over three hours. The infusion time can be gradually reduced to one hour if no infusion-associated reactions occur.

Idursulfase is the first human enzyme replacement therapy for Hunter syndrome. It is supplied in single vial packs, each vial containing 6mg of idursulfase in 3ml concentrate for solution for infusion.

Further information: Shire 01256 894000

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases